Download PDF

1. Company Snapshot

1.a. Company Description

NeuroOne Medical Technologies Corporation operates as a medical technology company.The company focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders.It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator for use with NeuroOne's combination recording and ablation electrode to record brain activity and ablate brain tissue using the same electrode.


The company is based in Eden Prairie, Minnesota.

Show Full description

1.b. Last Insights on NMTC

NeuroOne Medical Technologies Corporation's recent performance was driven by strong Q1 2026 earnings, with the company reporting a significant increase in revenue and profitability. The company's momentum stocks status, as designated by Zacks, further underscores its positive trajectory. Additionally, NeuroOne's inclusion in the Zacks Rank #1 (Strong Buy) list, along with other top-performing stocks, highlights its potential for growth. The company's institutional and insider ownership, while lower than some peers, suggests a relatively stable ownership structure.

1.c. Company Highlights

2. NeuroOne's Q1 FY2026 Earnings: A Closer Look at Financial Performance

NeuroOne Medical Technologies Corporation reported product revenue of $2,900,000 in Q1 FY2026, representing a 5.5% increase from the previous quarter. The company's net loss was $1,400,000, or $0.03 per share, compared to net income of $1,800,000, or $0.06 per share, in the same quarter of the prior year. The actual EPS of -$0.03 beat estimates of -$0.04. Product gross profit was $1,600,000, or 54.2% of revenue, indicating a relatively stable margin.

Publication Date: Mar -08

📋 Highlights
  • Revenue Growth:: Q1 FY2026 product revenue rose to $2.9M, a 5.5% increase from the previous quarter.
  • Net Loss Widened:: Net loss reached $1.4M ($0.03/share) vs. net income of $1.8M ($0.06/share) in Q1 FY2025.
  • 2026 Sales Guidance:: Projected FY2026 sales of at least $10.5M, a minimum 17% increase over FY2025.
  • 1RF Brain Ablation Adoption:: Nearly 50% of all ablations since launch occurred in Q1 FY2026, indicating strong market penetration.
  • Trigeminal Nerve Ablation Success:: 9 patients treated with 100% pain-free outcomes, with potential licensing discussions underway.

Business Progress and Outlook

The company is making progress in various areas, including their 1RF brain ablation system, which has seen increased adoption and penetration in the market. The number of ablations performed in fiscal Q1 2026 was nearly half of all ablations performed since the launch of the technology. NeuroOne is projecting fiscal year 2026 sales to be at least $10,500,000, a minimum 17% increase from fiscal year 2025, and analysts estimate next year's revenue growth at 31.9%.

Key Developments and Partnerships

The company's 1RF trigeminal nerve ablation system has shown promising results in treating facial pain, with nine patients treated and all reporting being pain-free. NeuroOne is in diligence discussions with a strategic partner to potentially license this technology. Additionally, their drug delivery program has been accelerated, with devices expected to be available for commercial use in investigational clinical studies or animals in Q3 FY2026.

Valuation and Financial Health

With a P/S Ratio of 4.88, the market is pricing in significant revenue growth, which is supported by the company's guidance and analyst estimates. The EV/EBITDA ratio of -5.75 indicates that the company's valuation is sensitive to its ability to generate earnings. NeuroOne had cash and cash equivalents of $3,600,000 as of December 31, 2025, and is funded through fiscal 2026, providing a stable financial foundation.

Operating Expenses and Future Expectations

Total operating expenses were $3,300,000, with research and development expense at $1,400,000. The company expects SG&A to be fairly flat for the rest of the year, but R&D expenses to fluctuate depending on project phases. With the burden of promotion and marketing costs lying with their partner, Zimmer, NeuroOne is well-positioned to manage its operating expenses.

3. NewsRoom

Card image cap

NeuroOne Medical Technologies Corporation (NMTC) Discusses Platform Technology Advancements and Growth Plans for Neurological Device Applications Transcript

Mar -12

Source: seekingalpha.com

Card image cap

Brokerages Set NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) PT at $1.98

Mar -05

Source: defenseworld.net

Card image cap

NeuroOne Medical Technologies Corporation (NMTC) Q1 2026 Earnings Call Transcript

Feb -17

Source: seekingalpha.com

Card image cap

NeuroOne Medical Technologies (NASDAQ:NMTC) versus Aclarion (NASDAQ:ACON) Head to Head Contrast

Feb -12

Source: defenseworld.net

Card image cap

Contrasting NeuroOne Medical Technologies (NASDAQ:NMTC) and Cannlabs (OTCMKTS:CANL)

Jan -28

Source: defenseworld.net

Card image cap

Best Momentum Stocks to Buy for January 6th

Jan -06

Source:

Card image cap

New Strong Buy Stocks for January 6th

Jan -06

Source: zacks.com

Card image cap

NeuroOne Medical Technologies Corporation (NMTC) Q4 2025 Earnings Call Transcript

Dec -17

Source: seekingalpha.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (9.49%)

6. Segments

Strip/Grid Products, Stereoelectrocencephalography Products and Electrode Cable Assembly Products

Expected Growth: 9.0%

NeuroOne Medical Technologies Corporation's Strip/Grid Products, Stereoelectrocencephalography Products, and Electrode Cable Assembly Products are driven by increasing demand for minimally invasive neurosurgical procedures, advancements in EEG technology, and growing adoption of precision medicine. The 9.0% growth rate is also fueled by expanding applications in neurology, psychiatry, and sleep disorder diagnosis, as well as increasing investments in research and development.

Collaborations

Expected Growth: 10.47%

NeuroOne Medical Technologies Corporation's 10.47% growth is driven by strategic collaborations, expanding product portfolio, and increasing adoption of minimally invasive neurosurgical technologies. Partnerships with leading medical institutions and research organizations have accelerated innovation, while growing demand for neurodiagnostic and neuromodulation solutions has fueled revenue growth.

7. Detailed Products

Cortex

A thin-film electrode array designed for chronic recording and stimulation of the brain, providing high-resolution neural signals for research and clinical applications.

Syringe Electrode

A minimally invasive, injectable electrode for recording and stimulating neural activity, suitable for a wide range of applications, including neurology, psychiatry, and neurosurgery.

NeuroLite

A thin, flexible, and lightweight electrode array designed for acute and chronic neural recording and stimulation, suitable for a variety of applications, including brain-computer interfaces and neuroprosthetics.

8. NeuroOne Medical Technologies Corporation's Porter Forces

Forces Ranking

Threat Of Substitutes

NeuroOne Medical Technologies Corporation operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the ongoing development of new technologies.

Bargaining Power Of Customers

NeuroOne Medical Technologies Corporation's customers are primarily hospitals and medical institutions, which have limited bargaining power due to the specialized nature of the company's products.

Bargaining Power Of Suppliers

NeuroOne Medical Technologies Corporation relies on a few key suppliers for its raw materials, which gives them some bargaining power, but the company's strong relationships with its suppliers mitigate this risk.

Threat Of New Entrants

The medical technology industry has high barriers to entry, including significant research and development costs, regulatory hurdles, and the need for specialized expertise, making it difficult for new entrants to compete with NeuroOne Medical Technologies Corporation.

Intensity Of Rivalry

The medical technology industry is highly competitive, with several established players competing for market share, which increases the intensity of rivalry for NeuroOne Medical Technologies Corporation.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 2.87%
Debt Cost 3.95%
Equity Weight 97.13%
Equity Cost 9.24%
WACC 9.08%
Leverage 2.95%

11. Quality Control: NeuroOne Medical Technologies Corporation passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
BioSig Technologies

A-Score: 4.8/10

Value: 8.0

Growth: 6.9

Quality: 3.8

Yield: 0.0

Momentum: 10.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Nevro

A-Score: 4.5/10

Value: 7.4

Growth: 4.6

Quality: 3.3

Yield: 0.0

Momentum: 9.0

Volatility: 2.7

1-Year Total Return ->

View Full Report
Stock-Card
NeuroOne Medical Technologies

A-Score: 4.0/10

Value: 6.8

Growth: 5.7

Quality: 4.2

Yield: 0.0

Momentum: 6.0

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
ClearPoint Neuro

A-Score: 3.9/10

Value: 6.0

Growth: 4.4

Quality: 4.1

Yield: 0.0

Momentum: 8.0

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Cytek Biosciences

A-Score: 3.7/10

Value: 5.7

Growth: 7.0

Quality: 4.0

Yield: 0.0

Momentum: 3.5

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Accelerate Diagnostics

A-Score: 3.4/10

Value: 10.0

Growth: 5.4

Quality: 5.0

Yield: 0.0

Momentum: 0.0

Volatility: 0.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

0.8$

Current Price

0.8$

Potential

-0.00%

Expected Cash-Flows